Pancreatic cancer tumors show distinct biological differences depending on a patient's racial background, according to new research from the University of Cincinnati Cancer Center that could pave the way for more tailored treatments.

The findings, published in the journal Cancer Research, come from a large-scale analysis of tens of thousands of biological markers across a diverse group of pancreatic cancer patients. The study was led by Nina Steele, PhD, an assistant professor in UC's College of Medicine, who spoke about the work with Spectrum News.

"We didn't have an accurate reflection of all of the patients impacted by the disease reflected in the data," Steele told Spectrum News. "There had never been a large-scale multiomic effort looking at tens of thousands of biological markers across a diverse cohort of pancreatic cancer patients."

Steele and colleagues at Henry Ford Health, where the project began, and UC mapped the genomic information of a sample designed to represent the American population diagnosed with pancreatic cancer. Pancreatic cancer is about 20% more likely to develop in Black African Americans (BAA), according to the researchers.

The team found that the cancer cells of Black African American patients and non-African American patients had different molecular signatures. Specifically, the markers that were more active in Black patients likely represent a type of cell typically associated with drug resistance, Steele said.

"The markers upregulated in Black patients likely represent a type of cells typically associated with drug resistance, so this biological difference could play a role in outcomes," Steele said.

For university students, especially those studying medicine, biology, or public health, the research underscores a growing push toward precision medicine that accounts for genetic and ancestral diversity. It also highlights an ongoing gap: many large-scale genomic studies have historically lacked diverse participant pools, which can lead to treatments that are less effective for certain populations.

The findings suggest that future pancreatic cancer therapies might need to be tailored based on a patient's molecular profile rather than a one-size-fits-all approach. The study also adds to a body of evidence showing that biological differences, not just social or economic factors, may contribute to disparities in cancer outcomes.

Steele's work was featured by Spectrum News, and the university noted that the research could open the door to more personalized treatments for a disease that remains one of the deadliest cancers. According to the American Cancer Society, pancreatic cancer has a five-year survival rate of around 12%, making new treatment approaches urgently needed.

The University of Cincinnati Cancer Center has been increasingly active in pancreatic cancer research. Earlier this year, UC researchers contributed to the FDA approval of daraxonrasib, a new pancreatic cancer drug, and are involved in clinical trials targeting the KRAS genetic mutation.

Steele's study is one of the first to conduct such a broad multiomic analysis across a racially diverse cohort of pancreatic cancer patients, according to the university. The research was supported by Henry Ford Health and the University of Cincinnati.